Impact of a Basal-Bolus Insulin Regimen on Metabolic Control and Risk of Hypoglycemia in Patients With Diabetes Undergoing Peritoneal Dialysis.
Ana María Gómez, Santiago Vallejo, Freddy Ardila...
https://pubmed.ncbi.nlm.nih.gov/28927285/Actively Recruiting
Led by The People's Hospital of Gaozhou · Updated on 2025-07-22
70
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of using an amino acid 15 peritoneal dialysis solution in patients with diabetes who are undergoing peritoneal dialysis. This single-center, open, prospective, self-controlled clinical study aims to observe changes in glycosylated hemoglobin HbA1c 90 days after starting the amino acid dialysis solution. The study focuses on diabetic patients already receiving peritoneal dialysis to better understand how this treatment may influence blood sugar control and related health measures. Participants will use one bag 2 liters of amino acid 15 peritoneal dialysis solution daily after breakfast, followed by treatment with glucose peritoneal dialysis solution lactate. The study period involves monitoring patients from the start Day 0 through 90 days of treatment with this amino acid solution. This intervention is assessed without a comparison group, as each patient serves as their own control. During the study, participants will have regular assessments of blood markers including glycosylated hemoglobin, fasting blood glucose, serum albumin, hemoglobin, prealbumin, daily urine volume, ultrafiltration volume, Ktv, creatinine clearance rate Ccr, and hypoglycemic drug use. These measurements will be taken at baseline, 30 days, and 90 days to track changes over time. The total study duration for each participant is 90 days, with ongoing monitoring for safety and effectiveness of the amino acid dialysis solution.
CONDITIONS
Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients
S
Shanshan Deng
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The People's Hospital of Gaozhou
Lead Sponsor
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 90 days
Participants use a bag of amino acid peritoneal dialysis solution (2L) after breakfast daily, followed by treatment with glucose peritoneal dialysis solution.
Visits on Day 0, Day 30, and Day 90
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ana María Gómez, Santiago Vallejo, Freddy Ardila...
https://pubmed.ncbi.nlm.nih.gov/28927285/Uyen Duong, Rajnish Mehrotra, Miklos Z Molnar...
https://pubmed.ncbi.nlm.nih.gov/21511838/Ahad Qayyum, Tahseen A Chowdhury, Elizabeth Ley Oei...
https://pubmed.ncbi.nlm.nih.gov/26960210/The People's Hospital of Gaozhou
Lead Sponsor
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Collaborating Sponsor